HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions

Background: Recent studies have shown preliminary evidence that vaccination against human papillomavirus (HPV) could decrease the risk of persistent/recurrent HSIL in women treated for high-grade cervical intraepithelial lesion (HSIL). We aimed to determine the benefits of HPV vaccination in patient...

Descripción completa

Detalles Bibliográficos
Autores: Pino Saladrigues, Marta del, Martí, Cristina, Torras, Ines, Henere, Carla, Munmany, Meritxell, Marimon, Lorena, Saco, Adela, Torné Bladé, Aureli, Ordi i Majà, Jaume
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/174062
Acceso en línea:https://hdl.handle.net/2445/174062
Access Level:acceso abierto
Palabra clave:Vacuna del papil·lomavirus
Tumors
Papillomavirus vaccines
id ES_0dac2d7204e48bf38bde871360f97a33
oai_identifier_str oai:diposit.ub.edu:2445/174062
network_acronym_str ES
network_name_str España
repository_id_str
spelling HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life ConditionsPino Saladrigues, Marta delMartí, CristinaTorras, InesHenere, CarlaMunmany, MeritxellMarimon, LorenaSaco, AdelaTorné Bladé, AureliOrdi i Majà, JaumeVacuna del papil·lomavirusTumorsPapillomavirus vaccinesTumorsBackground: Recent studies have shown preliminary evidence that vaccination against human papillomavirus (HPV) could decrease the risk of persistent/recurrent HSIL in women treated for high-grade cervical intraepithelial lesion (HSIL). We aimed to determine the benefits of HPV vaccination in patients undergoing conization for HSIL in real-life conditions and evaluate vaccination compliance associated with different funding policies. Methods: From January 2013 to July 2018, 265 women underwent conization in our center. From January 2013 to July 2017, treated patients (n = 131) had to pay for the vaccine, whereas after July 2017 the vaccine was publicly funded and free for treated women (n = 134). Post-conization follow-up controls were scheduled every six months with a Pap smear, HPV testing, and a colposcopy. Results: 153 (57.7%) women accepted vaccination (vaccinated group), and 112 (42.3%) refused the vaccine (non-vaccinated group). Persistent/recurrent HSIL was less frequent in vaccinated than in non-vaccinated women (3.3% vs. 10.7%, p = 0.015). HPV vaccination was associated with a reduced risk of persistent/recurrent HSIL (OR 0.2, 95%CI: 0.1–0.7, p = 0.010). Vaccination compliance increased when the vaccine was publicly funded (from 35.9% [47/131] to 79.1% [106/134], p < 0.001). Conclusions: HPV vaccination in women undergoing conization is associated with a 4.5-fold reduction in the risk of persistent/recurrent HSIL. Vaccination policies have an important impact on vaccination compliance.MDPI2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/174062Articles publicats en revistes (Patologia i Terapèutica Experimental)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: http://dx.doi.org/10.3390/vaccines8020245Vaccines, 2020, vol. 8, num. 2http://dx.doi.org/10.3390/vaccines8020245cc by (c) Pino Saladrigues et al., 2020http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1740622026-05-27T06:46:51Z
dc.title.none.fl_str_mv HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions
title HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions
spellingShingle HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions
Pino Saladrigues, Marta del
Vacuna del papil·lomavirus
Tumors
Papillomavirus vaccines
Tumors
title_short HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions
title_full HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions
title_fullStr HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions
title_full_unstemmed HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions
title_sort HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions
dc.creator.none.fl_str_mv Pino Saladrigues, Marta del
Martí, Cristina
Torras, Ines
Henere, Carla
Munmany, Meritxell
Marimon, Lorena
Saco, Adela
Torné Bladé, Aureli
Ordi i Majà, Jaume
author Pino Saladrigues, Marta del
author_facet Pino Saladrigues, Marta del
Martí, Cristina
Torras, Ines
Henere, Carla
Munmany, Meritxell
Marimon, Lorena
Saco, Adela
Torné Bladé, Aureli
Ordi i Majà, Jaume
author_role author
author2 Martí, Cristina
Torras, Ines
Henere, Carla
Munmany, Meritxell
Marimon, Lorena
Saco, Adela
Torné Bladé, Aureli
Ordi i Majà, Jaume
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Vacuna del papil·lomavirus
Tumors
Papillomavirus vaccines
Tumors
topic Vacuna del papil·lomavirus
Tumors
Papillomavirus vaccines
Tumors
description Background: Recent studies have shown preliminary evidence that vaccination against human papillomavirus (HPV) could decrease the risk of persistent/recurrent HSIL in women treated for high-grade cervical intraepithelial lesion (HSIL). We aimed to determine the benefits of HPV vaccination in patients undergoing conization for HSIL in real-life conditions and evaluate vaccination compliance associated with different funding policies. Methods: From January 2013 to July 2018, 265 women underwent conization in our center. From January 2013 to July 2017, treated patients (n = 131) had to pay for the vaccine, whereas after July 2017 the vaccine was publicly funded and free for treated women (n = 134). Post-conization follow-up controls were scheduled every six months with a Pap smear, HPV testing, and a colposcopy. Results: 153 (57.7%) women accepted vaccination (vaccinated group), and 112 (42.3%) refused the vaccine (non-vaccinated group). Persistent/recurrent HSIL was less frequent in vaccinated than in non-vaccinated women (3.3% vs. 10.7%, p = 0.015). HPV vaccination was associated with a reduced risk of persistent/recurrent HSIL (OR 0.2, 95%CI: 0.1–0.7, p = 0.010). Vaccination compliance increased when the vaccine was publicly funded (from 35.9% [47/131] to 79.1% [106/134], p < 0.001). Conclusions: HPV vaccination in women undergoing conization is associated with a 4.5-fold reduction in the risk of persistent/recurrent HSIL. Vaccination policies have an important impact on vaccination compliance.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/174062
url https://hdl.handle.net/2445/174062
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: http://dx.doi.org/10.3390/vaccines8020245
Vaccines, 2020, vol. 8, num. 2
http://dx.doi.org/10.3390/vaccines8020245
dc.rights.none.fl_str_mv cc by (c) Pino Saladrigues et al., 2020
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Pino Saladrigues et al., 2020
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Patologia i Terapèutica Experimental)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403352834506752
score 15,301603

Similares en LA Referencia